MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ
0.8472
+0.0014
+0.17%
Closed 17:56 07/08 EDT
OPEN
0.8400
PREV CLOSE
0.8458
HIGH
0.8700
LOW
0.8300
VOLUME
432.51K
TURNOVER
0
52 WEEK HIGH
1.660
52 WEEK LOW
0.5526
MARKET CAP
109.43M
P/E (TTM)
-4.0790
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATOS last week (0630-0704)?
Weekly Report · 2d ago
Weekly Report: what happened at ATOS last week (0623-0627)?
Weekly Report · 06/30 10:37
Weekly Report: what happened at ATOS last week (0616-0620)?
Weekly Report · 06/23 10:32
Weekly Report: what happened at ATOS last week (0609-0613)?
Weekly Report · 06/16 10:36
Weekly Report: what happened at ATOS last week (0602-0606)?
Weekly Report · 06/09 10:37
Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)
TipRanks · 06/06 17:25
Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 06/06 10:50
Atossa Therapeutics Price Target Raised to $7.50/Share From $7.25 by Ascendiant Capital
Dow Jones · 06/06 10:50
More
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Webull offers Atossa Therapeutics Inc stock information, including NASDAQ: ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.